无症状高尿酸血症与心血管疾病和肾脏疾病关系的研究进展
杨洋, 龚艳春 . 无症状高尿酸血症与心血管疾病和肾脏疾病关系的研究进展[J]. 内科理论与实践, 2021 , 16(05) : 366 -370 . DOI: 10.16138/j.1673-6087.2021.05.016
[1] | Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic?[J]. Curr Opin Rheumatol, 2020, 32(1): 71-79. |
[2] | Waheed Y, Yang F, Sun D. The role of asymptomatic hyperuricemia in the progression of chronic kidney disease CKD and cardiovascular diseases CVD[EB/J]. Korean J Intern Med, 2020. https://www.researchgate.net/publication/346312158_The_role_of_asymptomatic_hyperuricemia_ in_the_progression_of_chronic_kidney_disease_CKD_and_cardiovascular_diseases_CVD. |
[3] | Pijak MR. A role for asymptomatic hyper-uricemia in the progression of cardiovascular and renal disease[J]. BMJ, 2020, 110(5 Pt 1): 2390-2397. |
[4] | Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review[J]. BMC Musculoskelet Disord, 2015, 16:296. |
[5] | Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, et al. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats[J]. J Biol Chem, 2019, 294(11): 4272-4281. |
[6] | Li H, Qian F, Liu H, et al. Elevated uric acid levels promote vascular smooth muscle cells (VSMC) proliferation via an nod-Like receptor protein 3 (NLRP3)-inflammasome-dependent mechanism[J]. Med Sci Monit, 2019, 25: 8457-8464. |
[7] | Braga TT, Forni MF, Correa-Costa M, et al. Soluble uric acid activates the NLRP3 inflammasome[J]. Sci Rep, 2017, 739884. |
[8] | Yang X, Gu J, Lv H, et al. Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor[J]. Biomed Pharmacother, 2019, 109: 1163-1170. |
[9] | Liang WY, Zhu XY, Zhang JW, et al. Uric acid promotes chemokine and adhesion molecule production in vascular endothelium via nuclear factor-kappa B signaling[J]. Nutr Metab Cardiovasc Dis, 2015, 25(2): 187-194. |
[10] | Sánchez-Lozada LG. The pathophysiology of uric acid on renal diseases[J]. Contrib Nephrol, 2018, 192: 17-24. |
[11] | Song M, Li N, Yao Y, et al. Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis[J]. J Cell Mol Med, 2019, 23(8): 4970-4979. |
[12] | Gancheva R, Kundurdjiev A, Ivanova M, et al. Evaluation of cardiovascular risk in stages of gout by a complex multimodal ultrasonography[J]. Rheumatol Int, 2017, 37(1): 121-130. |
[13] | Kim SC, Di Carli MF, Garg RK, et al. Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome[J]. BMC Rheumatol, 2018, 2: 17. |
[14] | Choi HY, Kim SH, Choi AR, et al. Hyperuricemia and risk of increased arterial stiffness in healthy women based on health screening in Korean population[J]. PLoS One, 2017, 12(6): e180406. |
[15] | Yan NW, Numthavaj P, Thakkinstian A. Association between uric acid and arterial stiffness in general adults: a systematic review and meta-analysis[J]. Ramathibodi Med J, 2018. https://www.researchgate.net/publication/333080340_Association_Between_Uric_Acid_and_Arterial_Stiffness_in_General_Adults_A_Systematic_Review_ and_Meta-analysis. |
[16] | Moriyama K. Low-density lipoprotein subclasses are associated with serum uric acid levels[J]. Clin Lab, 2018, 64(7): 1137-1144. |
[17] | Tayefi M, Hassanian SM, Maftouh M, et al. Relationship between platelet count and platelet width distribution and serum uric acid concentrations in patients with untreated essential hypertension[J]. Biofactors, 2018, 44(6): 532-538. |
[18] | Park JS, Kang S, Ahn CW, et al. Relationships between serum uric acid, adiponectin and arterial stiffness in postmenopausal women[J]. Maturitas, 2012, 73(4): 344-348. |
[19] | Feldman RD. Sex-specific determinants of coronary artery disease and atherosclerotic risk factors: estrogen and beyond[J]. Can J Cardiol, 2020, 36(5): 706-711. |
[20] | Tanaka A, Taguchi I, Teragawa H, et al. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: a randomized, controlled trial[J]. PLoS Med, 2020, 17(4): e1003095. |
[21] | McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology[J]. Eur Heart J, 2012, 33(14): 1787-1847. |
[22] | Wu X, Jian G, Tang Y, et al. Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities[J]. Nutr Metab Cardiovasc Dis, 2020, 30(4): 666-673. |
[23] | Pan JA, Lin H, Wang CQ, et al. Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia[J]. Heart Vessels, 2020: 35(10):1446-1453. |
[24] | Jörgensen G. Serum uric acid concentrations can predict hypertension: a longitudinal population-based epidemiological study[J]. Horm Metab Res, 2017, 49(11): 873-879. |
[25] | Zhang J, Diao B, Lin X, et al. TLR2 and TLR4 mediate an activation of adipose tissue renin-angiotensin system induced by uric acid[EB/J]. Biochimie, 2019. https://linkinghub.elsevier.com/retrieve/pii/S0300-9084(19)30127-0. |
[26] | Mercuro G, Vitale C, Cerquetani E, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk[J]. Am J Cardiol, 2004, 94(7): 932-935. |
[27] | Xu C, Lu A, Lu X, et al. Activation of renal (pro)renin receptor contributes to high fructose-induced salt sensitivity[J]. Hypertension, 2017, 69(2): 339-348. |
[28] | Mazza A, Lenti S, Schiavon L, et al. Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population[J]. Biomed Pharmacother, 2017, 86: 590-594. |
[29] | Cicero AF, Salvi P, D’Addato S, et al. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study[J]. J Hypertens, 2014, 32(1): 57-64. |
[30] | Storhaug HM, Norvik JV, Toft I, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population[J]. BMC Cardiovasc Disord, 2013, 13:115. |
[31] | Tu W, Wu J, Jian G, et al. Asymptomatic hyperuricemia and incident stroke in elderly Chinese patients without comorbidities[J]. Eur J Clin Nutr, 2019, 73(10): 1392-1402. |
[32] | Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis[J]. Sci Rep, 2016, 6: 19520. |
[33] | Gómez M, Vila J, Elosua R, et al. Relationship of lipid oxidation with subclinical atherosclerosis and 10-year coronary events in general population[J]. Atherosclerosis, 2014, 232(1): 134-140. |
[34] | Suarna C, Dean RT, May J, et al. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate[J]. Arterioscler Thromb Vasc Biol, 1995, 15(10): 1616-1624. |
[35] | Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis[J]. Cardiovasc Ther, 2012, 30(4): 217-226. |
[36] | Kuwano K, Ikeda H, Oda T, et al. Xanthine oxidase mediates cyclic flow variations in a canine model of coronary arterial thrombosis[J]. Am J Physiol, 1996, 270(6 Pt 2): H1993-H1999. |
[37] | Wu J, Lei G, Wang X, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities[J]. Oncotarget, 2017, 8(46): 80688-80699. |
[38] | Rodríguez-Martín S, de Abajo FJ, Gil M, et al. Risk of acute myocardial infarction among new users of allopurinol according to serum urate level[J]. J Clin Med, 2019, 8(12): 2150. |
[39] | Miranda-Aquino T, Pérez-Topete SE, González-Padilla C, et al. Asymptomatic hyperuricaemia and coronary artery disease[J]. Reumatol Clin (Engl Ed), 2020, 17(5): 263-267. |
[40] | Gaubert M, Marlinge M, Alessandrini M, et al. Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome[J]. Purinergic Signal, 2018, 14(2):191-199. |
[41] | Jung SW, Kim SM, Kim YG, et al. Uric acid and inflammation in kidney disease[J]. Am J Physiol Renal Physiol, 2020, 318(6): F1327-F1340. |
[42] | Bonino B, Leoncini G, Russo E, et al. Uric acid in CKD: has the jury come to the verdict?[J]. J Nephrol, 2020, 33(4): 715-724. |
[43] | Hu C, Wu X. Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue[J]. Int Urol Nephrol, 2019, 51(12): 2227-2233. |
[44] | Petreski T, Ekart R, Hojs R, et al. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis[J]. Int Urol Nephrol, 2019, 51(6): 1013-1018. |
[45] | Liu X, Wang H, Ma R, et al. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5[J]. Clin Exp Nephrol, 2019, 23(3): 362-370. |
[46] | Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease[J]. N Engl J Med, 2020, 382(26): 2504-2513. |
[47] | Eleftheriadis T, Golphinopoulos S, Pissas G, et al. Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial[J]. J Adv Res, 2017, 8(5): 555-560. |
[48] | Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia[J]. Am J Kidney Dis, 2018, 72(6): 798-810. |
[49] | FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout[J]. Arthritis Care Res(Hoboken), 2020, 72(6): 744-760. |
[50] | Hisatome I, Li P, Miake J, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease: Japanese guideline on the management of asymptomatic hyperuricemia[J]. Circ J, 2021, 85(2): 130-138. |
/
〈 |
|
〉 |